Literature DB >> 15115635

Prophylactic migraine therapy: emerging treatment options.

Marcelo E Bigal1, Abouch V Krymchantowski, Alan M Rapoport.   

Abstract

In this paper, new treatment options for migraine prevention are reviewed. An overview about migraine pathophysiology is provided and current indications for migraine prevention and new and upcoming preventive medications are discussed briefly. Data are presented on topiramate, levetiracetam, zonisamide, botulinim toxin, tizanidine, nefazodone, lisinopril, candesartan, carabersat, petasites, and coenzyme Q.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15115635     DOI： 10.1007/s11916-004-0049-1

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN： 1534-3081


  40 in total

1.  An open-label dose-titration study of the efficacy and tolerability of tizanidine hydrochloride tablets in the prophylaxis of chronic daily headache.

Authors:  J R Saper; P K Winner; A E Lake
Journal:  Headache       Date:  2001-04       Impact factor: 5.887

2.  Brain stem activation in spontaneous human migraine attacks.

Authors:  C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

3.  Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.

Authors:  W J Binder; M F Brin; A Blitzer; L D Schoenrock; J M Pogoda
Journal:  Otolaryngol Head Neck Surg       Date:  2000-12       Impact factor: 3.497

4.  Nefazodone for chronic daily headache prophylaxis: an open-label study.

Authors:  J R Saper; A E Lake; S J Tepper
Journal:  Headache       Date:  2001-05       Impact factor: 5.887

5.  Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura.

Authors:  S Paterna; P Di Pasquale; A D'Angelo; G Seidita; A Tuttolomondo; A Cardinale; T Maniscalchi; G Follone; A Giubilato; M Tarantello; G Licata
Journal:  Eur Neurol       Date:  2000       Impact factor: 1.710

Review 6.  The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation.

Authors:  A May; P J Goadsby
Journal:  J Cereb Blood Flow Metab       Date:  1999-02       Impact factor: 6.200

7.  Medical consultation for migraine: results from the American Migraine Study.

Authors:  R B Lipton; W F Stewart; D Simon
Journal:  Headache       Date:  1998-02       Impact factor: 5.887

8.  Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.

Authors:  Joel R Saper; Alvin E Lake; Deborah T Cantrell; Paul K Winner; Jeffery R White
Journal:  Headache       Date:  2002-06       Impact factor: 5.887

9.  Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases.

Authors:  Stewart J Tepper; Marcelo E Bigal; Fred D Sheftell; Alan M Rapoport
Journal:  Headache       Date:  2004-09       Impact factor: 5.887

Review 10.  Magnetic resonance spectroscopy studies in migraine.

Authors:  P Montagna; P Cortelli; B Barbiroli
Journal:  Cephalalgia       Date:  1994-06       Impact factor: 6.292
View more
  4 in total

1.  Treating epilepsy in the setting of medical comorbidities.

Authors:  Nivedita U Jerath; Dronacharya Lamichhane; Madhu Jasti; Vinusha Yarlagadda; Eduardo Zilli; Yara Nazzal; Mark Granner
Journal:  Curr Treat Options Neurol       Date:  2014-07       Impact factor: 3.598

Review 2.  Chronic disorders with episodic manifestations: focus on epilepsy and migraine.

Authors:  Sheryl R Haut; Marcelo E Bigal; Richard B Lipton
Journal:  Lancet Neurol       Date:  2006-02       Impact factor: 44.182

Review 3.  Medication overuse headache: awareness, detection and treatment.

Authors:  Alan M Rapoport
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 4.  Migraine headache prophylaxis: current options and advances on the horizon.

Authors:  Nabih M Ramadan
Journal:  Curr Neurol Neurosci Rep       Date:  2006-03       Impact factor: 5.081
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.